Gan & Lee Pharmaceuticals

8 articles about Gan & Lee Pharmaceuticals

• Gan & Lee Pharmaceuticals Concludes Phase 3 Studies of Gan & Lee Insulin Glargine (GL-GLA)

  10/14/2021

  Gan & Lee Pharmaceuticals Co., Ltd. is pleased to announce the completion of two randomized, multicenter, phase 3 studies that compare proposed biosimilar Gan & Lee insulin glargine (GL-GLA) to a reference biologic.

• Gan & Lee Pharmaceuticals to present data at the 57th Annual European Association for the Study of Diabetes Meeting

  9/9/2021

  Gan & Lee Pharmaceuticals Co., Ltd., is excited to present positive data from five abstracts which will be featured as short oral discussions at the 57th Annual European Association for the Study of Diabetes Meeting.

• Gan & Lee receives EMA orphan drug designation for Phase I drug candidate GLR2007 for the treatment of glioma

  4/6/2021

   Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), a global biopharmaceutical company, today announced that the European Medicine Agency (EMA) Committee for Orphan Medicinal Products granted orphan drug designation for the investigational compound GLR2007

• Gan & Lee Announces New Partnership with International Diabetes Federation

  2/22/2021

  Gan & Lee Pharmaceuticals Co., Ltd., a global biopharmaceutical company, has announced a collaborative partnership with the International Diabetes Federation that aims to support their global efforts of promoting diabetes care and prevention worldwide.

• Phase 1 Drug Candidate GLR2007 Developed by Gan & Lee has been Granted Fast Track Designation by the U.S. FDA

  1/29/2021

  Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee) ( Shanghai : 603087.SH), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for GLR2007, for the treatment of patients with glioblastoma. GLR2007 is

• Gan & Lee Pharmaceuticals Initiates First-in Human Phase 1 Clinical Trial for New Anti-tumor Drug GLR2007

  7/30/2020

  Today marks a major milestone for Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), with the initiation of our first-in-human Phase 1 clinical trial for GLR2007, our internally-invented, cyclin-dependent kinase 4/6 (CDK4/6) inhibitor as a potential therapy for advanced solid tumors.

• Qiming's Portfolio Company Gan & Lee Pharmaceuticals Lands A-Shares Main Board

  6/29/2020

  Chinese insulin manufacturer Gan & Lee Pharmaceuticals, Qiming's portfolio company lands on the A-shares main board market. The issue price of Gan & Lee is RMB 63.32 per share.

• Chinese Companies Gan & Lee Pharmaceuticals, Sino Biopharmaceuticals Ltd. Get Caught Up in Corruption Allegations

  9/12/2013